FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan Poolman

Research Profile

Living Beings

Chemicals & Drugs

Concepts & Ideas

Molecular Sequence Data

Procedures

Disorders

Meningococcal Infections

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Kerstin Hubert; Ines Mordhorst; Jan Poolman; Christine Tans; Jan Tommassen; Ulrich Vogel; Guy Baudoux; Nathalie Devos; Christiane Feron; Karine Goraj; Vincent E Weynants
ZnuD, a Potential Candidate for a Simple and Universal Neisseria meningitidis Vaccine.
Nathalie Devos; Christiane Feron; Patricia Momin; Michel Plisnier; Christine Tans; Vincent E Weynants; Jan Poolman
Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression.
Ray Borrow; Ron Dagan; Hans Hallander; Fred Zepp; Jan Poolman
Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan Poolman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kerstin Hubert; Ines Mordhorst; Jan Poolman; Christine Tans; Jan Tommassen; Ulrich Vogel; Guy Baudoux; Nathalie Devos; Christiane Feron; Karine Goraj; Vincent E Weynants
ZnuD, a Potential Candidate for a Simple and Universal Neisseria meningitidis Vaccine.
Infection and immunity 2013;81(6):1915-27.
2012: Nathalie Devos; Christiane Feron; Patricia Momin; Michel Plisnier; Christine Tans; Vincent E Weynants; Jan Poolman
Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression.
Microbes and infection / Institut Pasteur 2012;14(11):979-88.
2011: Ray Borrow; Ron Dagan; Hans Hallander; Fred Zepp; Jan Poolman
Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.
Expert review of vaccines 2011;10(11):1621-31.
2011: Philippe A Denoël; Fabrice Godfroid; Philippe Hermand; Vincent Verlant; Jan Poolman
Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides.
Vaccine 2011;29(38):6451-3.
2011: Philippe A Denoël; Lara Doyle; Dale Martin; Mario T Philipp; G Carletti; Jan Poolman
A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
Vaccine 2011;29(33):5495-501.
2011: Jan Poolman; Vincent E Weynants; Isabel De Vleeschauwer; Nathalie Devos; Nathalie Durant; Christiane Feron; Pascal Lestrate; Dominique Boutriau
Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.
Clinical and vaccine immunology : CVI 2011;18(7):1108-17.
2011: Jan Poolman; Ray Borrow
Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.
Expert review of vaccines 2011;10(3):307-22.
2011: Terry Nolan; Peter Richmond; Helen Marshall; Jodie McVernon; Karyn Alexander; Narcisa Mesaros; Emmanuel Aris; Jacqueline Miller; Jan Poolman; Dominique Boutriau
Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.
The Pediatric infectious disease journal 2011;30(3):190-6.
2011: Jan Poolman; Carl Frasch; Anu Nurkka; Helena Käyhty; Ralph Biemans; Lode Schuerman
Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.
Clinical and vaccine immunology : CVI 2011;18(2):327-36.
2011: Charles E Rose; Sandra Romero-Steiner; Robert L Burton; George M Carlone; David Goldblatt; Moon H Nahm; Lindsey Ashton; Mitch Haston; Nina Ekström; Raili Haikala; Helena Käyhty; Isabelle Henckaerts; Nathalie Durant; Jan Poolman; Phil Fernsten; Xinhong Yu; Branda T Hu; Kathrin U Jansen; Milan Blake; Elles R Simonetti; Peter W M Hermans; Brian D Plikaytis
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.
Clinical and vaccine immunology : CVI 2011;18(1):135-42.
2011: Fabrice Godfroid; Philippe Hermand; Vincent Verlant; Philippe Denoël; Jan Poolman
Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.
Infection and immunity 2011;79(1):238-45.
2010: Pablo Bonvehí; Dominique Boutriau; Javier Casellas; Vincent E Weynants; Christiane Feron; Jan Poolman
Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.
Clinical and vaccine immunology : CVI 2010;17(9):1460-6.
2010: Gary S Marshall; Colin D Marchant; Mark Blatter; Emmanuel Aris; Dominique Boutriau; Jan Poolman; Leonard R Friedland; Jacqueline M Miller
Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.
The Pediatric infectious disease journal 2010;29(5):469-71.
2010: Michiel Stork; Martine P Bos; Ilse Jongerius; Natasja de Kok; Ingrid Schilders; Vincent E Weynants; Jan Poolman; Jan Tommassen
An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential.
PLoS pathogens 2010;6():e1000969.
2010: Jan Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.
Clinical and vaccine immunology : CVI 2010;17(1):134-42.
2009: Roman Prymula; Paula Kriz; Eva Kaliskova; Thierry Pascal; Jan Poolman; Lode Schuerman
Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age.
Vaccine 2009;28(1):71-8.
2009: Jan Poolman; Pavla Kriz; Christiane Feron; Emmanuel Di-Paolo; Isabelle Henckaerts; Agnes Miseur; Dominique Wauters; Roman Prymula; Lode Schuerman
Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics.
Vaccine 2009;27(24):3213-22.
2009: V Weynants; Philippe A Denoël; N Devos; D Janssens; C Feron; K Goraj; P Momin; D Monnom; C Tans; A Vandercammen; F Wauters; Jan Poolman
Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.
Infection and immunity 2009;77(5):2084-93.
2009: Maria Lucia C Tondella; George M Carlone; N Messonnier; Conrad P Quinn; Bruce D Meade; D L Burns; J D Cherry; N Guiso; E L Hewlett; Kathryn M Edwards; D Xing; A Giammanco; C H Wirsing von König; L Han; L Hueston; J B Robbins; M Powell; C M Mink; Jan Poolman; S W Hildreth; Freyja Lynn; A Morris
International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.
Vaccine 2009;27(6):803-14.
2009: Lars Ostergaard; Edouard Lebacq; Jan Poolman; Gudrun Maechler; Dominique Boutriau
Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
Vaccine 2009;27(1):161-8.
2008: Maija Toropainen; Anna Raitolehto; Isabelle Henckaerts; Dominique Wauters; Jan Poolman; Pascal Lestrate; Helena Käyhty
Pneumococcal Haemophilus influenzae protein D conjugate vaccine induces antibodies that inhibit glycerophosphodiester phosphodiesterase activity of protein D.
Infection and immunity 2008;76(10):4546-53.
2008: Ron Dagan; Jan Poolman; Fred Zepp
Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.
Expert review of vaccines 2008;7(1):97-115.
2007: Terry Nolan; Stephen Lambert; Don Roberton; Helen Marshall; Peter Richmond; Catherine Streeton; Jan Poolman; Dominique Boutriau
A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.
Vaccine 2007;25(51):8487-99.
2007: Jamie Findlow; Ann Holland; Nick Andrews; Vincent E Weynants; Franklin Sotolongo; Paul Balmer; Jan Poolman; Ray Borrow
Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay.
Clinical and vaccine immunology : CVI 2007;14(11):1451-7.
2007: Vincent E Weynants; Christiane M Feron; Karine K Goraj; Martine P Bos; Philippe A Denoël; Vincent G Verlant; Jan Tommassen; Ian R A Peak; Ralph C Judd; Michael P Jennings; Jan Poolman
Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.
Infection and immunity 2007;75(11):5434-42.
2007: Philippe A Denoël; David Goldblatt; Isabel de Vleeschauwer; Jeanne-Marie Jacquet; Michael E Pichichero; Jan Poolman
Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.
Clinical and vaccine immunology : CVI 2007;14(10):1362-9.
2007: Ake Ortqvist; Isabelle Henckaerts; Jonas Hedlund; Jan Poolman
Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
Vaccine 2007;25(13):2445-50.
2007: Isabelle Henckaerts; Nathalie Durant; Dany de Grave; Lode Schuerman; Jan Poolman
Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children.
Vaccine 2007;25(13):2518-27.
2007: Lode Schuerman; Roman Prymula; Viktor Chrobok; Ilse Dieussaert; Jan Poolman
Kinetics of the immune response following pneumococcal PD conjugate vaccination.
Vaccine 2007;25(11):1953-61.
2007: Lode Schuerman; Roman Prymula; Isabelle Henckaerts; Jan Poolman
ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media.
Vaccine 2007;25(11):1962-8.
2007: Jeroen Kortekaas; Annika Pettersson; Jenny van der Biezen; Vincent E Weynants; Peter van der Ley; Jan Poolman; Martine P Bos; Jan Tommassen
Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region.
Vaccine 2007;25(1):72-84.
2007: Dominique Boutriau; Jan Poolman; Ray Borrow; Jamie Findlow; Javier Diez Domingo; Joan Puig-Barberà; José María Baldó; Victoria Planelles; Angels Jubert; Julia Colomer; Angel Gil; Karin Levie; Anne-Diane Kervyn; Vincent E Weynants; Francisco Dominguez; Ramón Barberá; Franklin Sotolongo
Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.
Clinical and vaccine immunology : CVI 2007;14(1):65-73.
2006: Ray Borrow; G M Carlone; Nancy E Rosenstein; M Blake; Ian M Feavers; Diana Martin; W Zollinger; J Robbins; Ingeborg S Aaberge; Dan M Granoff; Elizabeth Miller; Bonnie B Plikaytis; L van Alphen; Jan Poolman; R Rappuoli; Lisa Danzig; J Hackell; B Danve; M Caulfield; S Lambert; David S Stephens
Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.
Vaccine 2006;24(24):5093-107.
2006: Laura A Novotny; Joseph A Jurcisek; Fabrice Godfroid; Jan Poolman; Philippe A Denoël; Lauren O Bakaletz
Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae.
Vaccine 2006;24(22):4804-11.
2006: Annika Pettersson; Jeroen Kortekaas; Vincent E Weynants; Pierre Voet; Jan Poolman; Martine P Bos; Jan Tommassen
Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB.
Vaccine 2006;24(17):3545-57.
2006: Roman Prymula; Pascal Peeters; Viktor Chrobok; Paula Kriz; Elena Novakova; Eva Kaliskova; Igor Kohl; Patricia Lommel; Jan Poolman; jean-paul prieels; Lode Schuerman
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Lancet 2006;367(9512):740-8.
2006: Isabelle Henckaerts; David Goldblatt; Lindsey Ashton; Jan Poolman
Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.
Clinical and vaccine immunology : CVI 2006;13(3):356-60.
2005: Philippe A Denoël; Fabrice Godfroid; Nicole Guiso; Hans O Hallander; Jan Poolman
Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
Vaccine 2005;23(46-47):5333-41.
2005: Fabrice Godfroid; Philippe A Denoël; Jan Poolman
Are vaccination programs and isolate polymorphism linked to pertussis re-emergence?
Expert review of vaccines 2005;4(5):757-78.
2004: Anu Nurkka; Jaana Joensuu; Isabelle Henckaerts; Pascal Peeters; Jan Poolman; Terhi Kilpi; Helena Käyhty
Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants.
The Pediatric infectious disease journal 2004;23(11):1008-14.
2004: Fabrice Godfroid; Philippe A Denoël; Dany de Grave; Lode Schuerman; Jan Poolman
Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses.
International journal of medical microbiology : IJMM 2004;294(5):269-76.
2003: Carine Capiau; Jan Poolman; Bernard Hoet; Hugues Bogaerts; Francis Andre
Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned.
Vaccine 2003;21(19-20):2273-87.
2003: Carla C A M Peeters; Patrick R Lagerman; Odo de Weers; Lukas A Oomen; Peter Hoogerhout; Michel Beurret; Jan Poolman; Karen Reddin
Preparation of polysaccharide-conjugate vaccines.
Methods in molecular medicine 2003;87():153-74.
2002: Philippe A Denoël; Jan Poolman; G Carletti; K Veitch
Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection.
Vaccine 2002;20(19-20):2551-5.
2001: Jan Poolman; A Kaufhold; Dany de Grave; D Goldblatt
Clinical relevance of lower Hib response in DTPa-based combination vaccines.
Vaccine 2001;19(17-19):2280-5.
2000: EM Rouppe van der Voort; Margje Schuller; J Holst; P de Vries; Peter van der Ley; Germie van den Dobbelsteen; Jan Poolman
Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys.
Vaccine 2000;18(14):1334-43.
1999: Michael P Jennings; Yogitha N Srikhanta; ER Moxon; M Kramer; Jan Poolman; Betsy Kuipers; Peter van der Ley
The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis.
Microbiology (Reading, England) 1999;145 ( Pt 11)():3013-21.
1999: C C Peeters; I J Claassen; Margje Schuller; G F Kersten; EM van der Voort; Jan Poolman
Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice.
Vaccine 1999;17(20-21):2702-12.
1999: Keith Cartwright; Rhonwen Morris; H Rümke; A Fox; Ray Borrow; NT Begg; Peter Richmond; Jan Poolman
Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.
Vaccine 1999;17(20-21):2612-9.
1999: Nicole Guiso; Carine Capiau; G Carletti; Jan Poolman; P Hauser
Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines.
Vaccine 1999;17(19):2366-76.
1999: Andrew J Pollard; R Galassini; EM Rouppe van der Voort; Martin L Hibberd; Robert Booy; Paul Langford; Simon Nadel; Catherine A Ison; J Simon Kroll; Jan Poolman; Michael Levin
Cellular immune responses to Neisseria meningitidis in children.
Infection and immunity 1999;67(5):2452-63.
1999: Andrew J Pollard; R Galassini; E M van der Voort; Robert Booy; Paul Langford; Simon Nadel; Catherine A Ison; J Simon Kroll; Jan Poolman; Michael Levin
Humoral immune responses to Neisseria meningitidis in children.
Infection and immunity 1999;67(5):2441-51.
1999: Jordan W Tappero; Rosanna Lagos; A M Ballesteros; Bonnie B Plikaytis; D Williams; Janet K Dykes; Linda L Gheesling; George M Carlone; E Arne Høiby; J Holst; Hanne Nøkleby; Einar Rosenqvist; V.Gustavo Sierra; Concepción Campa; Franklin Sotolongo; J Vega; J Garcia; P Herrera; Jan Poolman; Bradley A Perkins
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
JAMA : the journal of the American Medical Association 1999;281(16):1520-7.
1998: M E Rodriguez; Germie van den Dobbelsteen; Lukas A Oomen; Odo de Weers; Leo van Buren; Michel Beurret; Jan Poolman; Peter Hoogerhout
Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response.
Vaccine 1998;16(20):1941-9.
1998: Odo de Weers; Michel Beurret; Leo van Buren; Lukas A Oomen; Jan Poolman; Peter Hoogerhout
Application of cystamine and N,N'-Bis(glycyl)cystamine as linkers in polysaccharide-protein conjugation.
Bioconjugate chemistry 1998;9(3):309-15.
1998: P Hauser; Dany de Grave; Fred Zepp; Jan Poolman; Moncef Slaoui
Development and efficacy assessment of combination vaccines, with emphasis on acellular pertussis.
Developments in biological standardization 1998;95():251-5.
1997: E R van der Voort; Harry van Dijken; Betsy Kuipers; Jenny van der Biezen; Peter van der Ley; J Meylis; I Claassen; Jan Poolman
Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine.
Infection and immunity 1997;65(12):5184-90.
1997: Jean van den Elsen; JN Herron; Peter Hoogerhout; Jan Poolman; Edwin Boel; Ton Logtenberg; J Wilting; Daan J A Crommelin; Jan Kroon; Piet Gros
Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: crystal structure of a Fab fragment in complex with a fluorescein-conjugated peptide.
Proteins 1997;29(1):113-25.
1997: Liana Steeghs; Michael P Jennings; Jan Poolman; Peter van der Ley
Isolation and characterization of the Neisseria meningitidis lpxD-fabZ-lpxA gene cluster involved in lipid A biosynthesis.
Gene 1997;190(2):263-70.
1997: Jean van den Elsen; E van Pomeren; Jan Poolman; J Wilting; JN Herron; Daan J A Crommelin
On the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis in outer membrane vesicles: a competitive fluorescence polarization immunoassay.
Analytical biochemistry 1997;247(2):382-8.
1997: EM Rouppe van der Voort; Betsy Kuipers; Humphrey F Brugghe; L M van Unen; hans timmermans; Peter Hoogerhout; Jan Poolman
Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines.
FEMS immunology and medical microbiology 1997;17(3):139-48.
1997: Annika Pettersson; Jan Poolman; Peter van der Ley; Jan Tommassen
Response of Neisseria meningitidis to iron limitation.
Antonie van Leeuwenhoek 1997;71(1-2):129-36.
1997: Peter van der Ley; M Kramer; A Martin; J C Richards; Jan Poolman
Analysis of the icsBA locus required for biosynthesis of the inner core region from Neisseria meningitidis lipopolysaccharide.
FEMS microbiology letters 1997;146(2):247-53.
1996: M C Schuch; Solange Barros Carbonare; Peter van der Ley; Paul Roholl; Jan Poolman; C A Vaz; Carlos A Moreira-Filho
Monoclonal antibodies against conserved epitopes of a 46-kDa protein from Neisseria meningitidis.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 1996;29(11):1485-90.
1996: Peter van der Ley; J van der Biezen; R Sutmuller; Peter Hoogerhout; Jan Poolman
Sequence variability of FrpB, a major iron-regulated outer-membrane protein in the pathogenic neisseriae.
Microbiology (Reading, England) 1996;142 ( Pt 11)():3269-74.
1996: C C Peeters; H C Rümke; L C Sundermann; E M Rouppe van der Voort; J Meulenbelt; Margje Schuller; A J Kuipers; Peter van der Ley; Jan Poolman
Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine.
Vaccine 1996;14(10):1009-15.
1996: I Claassen; J Meylis; Peter van der Ley; C Peeters; H Brons; J Robert; D Borsboom; A van der Ark; I van Straaten; Paul Roholl; Betsy Kuipers; Jan Poolman
Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.
Vaccine 1996;14(10):1001-8.
1996: E R van der Voort; Peter van der Ley; J van der Biezen; S George; O Tunnela; Harry van Dijken; Betsy Kuipers; Jan Poolman
Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
Infection and immunity 1996;64(7):2745-51.
1996: Peter van der Ley; M Kramer; Liana Steeghs; Betsy Kuipers; S R Andersen; Michael P Jennings; E R Moxon; Jan Poolman
Identification of a locus involved in meningococcal lipopolysaccharide biosynthesis by deletion mutagenesis.
Molecular microbiology 1996;19(5):1117-25.
1996: C C Peeters; P R Lagerman; Odo de Weers; Lukas A Oomen; Peter Hoogerhout; Michel Beurret; Jan Poolman
Polysaccharicb-conjugate vaccines.
Methods in molecular medicine 1996;4():111-33.
1996: Jan Poolman
Bacterial outer membrane protein vaccines. The meningococcal example.
Advances in experimental medicine and biology 1996;397():73-7.
1996: E J Wiertz; Alexei von Delwig; E M Donders; Humphrey F Brugghe; L M van Unen; hans timmermans; Mark Achtman; Peter Hoogerhout; Jan Poolman
T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins.
Infection and immunity 1996;64(1):298-304.
1995: Peter van der Ley; J van der Biezen; Jan Poolman
Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine.
Vaccine 1995;13(4):401-7.
1995: Jan Poolman
Development of a meningococcal vaccine.
Infectious agents and disease 1995;4(1):13-28.
1995: Jan Poolman; P Kriz-Kuzemenska; F Ashton; W Bibb; J Dankert; A Demina; L O Frøholm; M Hassan-King; D M Jones; I Lind
Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies.
Clinical and diagnostic laboratory immunology 1995;2(1):69-72.
1995: H J Hamstra; Betsy Kuipers; D Schijf-Evers; H G Loggen; Jan Poolman
The purification and protective capacity of Bordetella pertussis outer membrane proteins.
Vaccine 1995;13(8):747-52.
1994: Annika Pettersson; V Klarenbeek; J van Deurzen; Jan Poolman; Jan Tommassen
Molecular characterization of the structural gene for the lactoferrin receptor of the meningococcal strain H44/76.
Microbial pathogenesis 1994;17(6):395-408.
1994: AF Verheul; A J Kuipers; AK Braat; H A Dekker; C C Peeters; Harm Snippe; Jan Poolman
Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies.
Clinical and diagnostic laboratory immunology 1994;1(6):729-36.
1994: Michael P Jennings; Peter van der Ley; K E Wilks; Duncan J Maskell; Jan Poolman; E R Moxon
Cloning and molecular analysis of the galE gene of Neisseria meningitidis and its role in lipopolysaccharide biosynthesis.
Annals of the New York Academy of Sciences 1994;730():252-4.
1994: K H Kim; M K Park; C C Peeters; Jan Poolman; M H Shearer; R C Kennedy; M H Nahm
Comparison of nonhuman primate antibodies against Haemophilus influenzae type b polysaccharide with human antibodies in oligoclonality and in vivo protective potency.
Infection and immunity 1994;62(6):2426-31.
1994: Humphrey F Brugghe; hans timmermans; L M Van Unen; G J Ten Hove; G Van de Werken; Jan Poolman; Peter Hoogerhout
Simultaneous multiple synthesis and selective conjugation of cyclized peptides derived from a surface loop of a meningococcal class 1 outer membrane protein.
International journal of peptide and protein research 1994;43(2):166-72.
1993: Annika Pettersson; Peter van der Ley; Jan Poolman; Jan Tommassen
Molecular characterization of the 98-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis.
Infection and immunity 1993;61(11):4724-33.
1993: Michael P Jennings; Peter van der Ley; K E Wilks; Duncan J Maskell; Jan Poolman; E R Moxon
Cloning and molecular analysis of the galE gene of Neisseria meningitidis and its role in lipopolysaccharide biosynthesis.
Molecular microbiology 1993;10(2):361-9.
1993: Peter van der Ley; J van der Biezen; P Hohenstein; C Peeters; Jan Poolman
Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis.
Infection and immunity 1993;61(10):4217-24.
1993: AF Verheul; Harm Snippe; Jan Poolman
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.
Microbiological reviews 1993;57(1):34-49.
1993: AF Verheul; J A Van Gaans; E J Wiertz; Harm Snippe; Jan Verhoef; Jan Poolman
Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.
Infection and immunity 1993;61(1):187-96.
1993: C C Peeters; A M Tenbergen-Meekes; Jan Poolman; BJ Zegers; Ger T Rijkers
In vitro antibody response of human lymphocytes to the Haemophilus influenzae type b capsular polysaccharide.
Springer seminars in immunopathology 1993;15(2-3):247-58.
1993: E Wiertz; J van Gaans-van den Brink; Peter Hoogerhout; Jan Poolman
Microheterogeneity in the recognition of a HLA-DR2-restricted T cell epitope from a meningococcal outer membrane protein.
European journal of immunology 1993;23(1):232-9.
1992: J F Wang; D A Caugant; X Li; X Hu; Jan Poolman; B A Crowe; Mark Achtman
Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China.
Infection and immunity 1992;60(12):5267-82.
1992: M H Witvliet; M L Vogel; E J Wiertz; Jan Poolman
Interaction of pertussis toxin with human T lymphocytes.
Infection and immunity 1992;60(12):5085-90.
1992: Peter van der Ley; Jan Poolman
Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein.
Infection and immunity 1992;60(8):3156-61.
1992: E J Wiertz; J A van Gaans-van den Brink; H Gausepohl; A Prochnicka-Chalufour; Peter Hoogerhout; Jan Poolman
Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis.
The Journal of experimental medicine 1992;176(1):79-88.
1992: C C Peeters; A M Tenbergen-Meekes; Cobi J Heijnen; Jan Poolman; J M Zegers; Ger T Rijkers
Interferon-gamma and interleukin-6 augment the human in vitro antibody response to the Haemophilus influenzae type b polysaccharide.
The Journal of infectious diseases 1992;165 Suppl 1():S161-2.
1992: Dolf Evenberg; Peter Hoogerhout; Constant van Boeckel; Ger T Rijkers; E C Beuvery; J H van Boom; Jan Poolman
Preparation, antigenicity, and immunogenicity of synthetic ribosylribitol phosphate oligomer-protein conjugates and their potential use for vaccination against Haemophilus influenzae type b disease.
The Journal of infectious diseases 1992;165 Suppl 1():S152-5.
1992: C C Peeters; Dolf Evenberg; Peter Hoogerhout; H Käyhty; L Saarinen; Constant van Boeckel; G A van der Marel; J H van Boom; Jan Poolman
Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys.
Infection and immunity 1992;60(5):1826-33.
1992: C C Peeters; A M Tenbergen-Meekes; Cobi J Heijnen; Jan Poolman; BJ Zegers; Ger T Rijkers
In vitro activation of human T lymphocytes by Haemophilus influenzae type b capsular polysaccharides.
Scandinavian journal of immunology 1992;35(2):137-48.
1992: C C Peeters; A M Tenbergen-Meekes; Jan Poolman; BJ Zegers; Ger T Rijkers
Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide--protein conjugate vaccine is decreased by admixture of high doses of free saccharide.
Vaccine 1992;10(12):833-40.
1991: C C Peeters; A M Tenbergen-Meekes; Cobi J Heijnen; Jan Poolman; BJ Zegers; Ger T Rijkers
In vitro induction of a Haemophilus influenzae type b polysaccharide-specific antibody response in human peripheral blood lymphocytes of individuals recently vaccinated with an oligosaccharide-protein conjugate.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(12):4192-9.
1991: Jan Poolman; Peter van der Ley; E J Wiertz; Peter Hoogerhout
Second generation meningococcal OMP-LPS vaccines.
NIPH annals 1991;14(2):233-41.
1991: AF Verheul; Jan Poolman; Harm Snippe; Jan Verhoef
The influence of the adjuvant Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies.
Molecular immunology 1991;28(11):1193-200.
1991: AF Verheul; Gerardus Josephus Boons; G A Van der Marel; J H Van Boom; H J Jennings; Harm Snippe; Jan Verhoef; Peter Hoogerhout; Jan Poolman
Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.
Infection and immunity 1991;59(10):3566-73.
1991: C C Peeters; A M Tenbergen-Meekes; Jan Poolman; Michel Beurret; BJ Zegers; Ger T Rijkers
Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.
Infection and immunity 1991;59(10):3504-10.
1991: C C Peeters; A M Tenbergen-Meekes; B Haagmans; Dolf Evenberg; Jan Poolman; BJ Zegers; Ger T Rijkers
Pneumococcal conjugate vaccines.
Immunology letters 1991;30(2):267-74.
1991: E J Wiertz; J A van Gaans-van den Brink; G M Schreuder; A A Termijtelen; Peter Hoogerhout; Jan Poolman
T cell recognition of Neisseria meningitidis class 1 outer membrane proteins. Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(6):2012-8.
1991: Peter van der Ley; J E Heckels; Mumtaz Virji; Peter Hoogerhout; Jan Poolman
Topology of outer membrane porins in pathogenic Neisseria spp.
Infection and immunity 1991;59(9):2963-71.
1991: F E Ashton; L Mancino; A J Ryan; Jan Poolman; H Abdillahi; W D Zollinger
Serotypes and subtypes of Neisseria meningitidis serogroup B strains associated with meningococcal disease in Canada, 1977-1989.
Canadian journal of microbiology 1991;37(8):613-7.
1991: C C Peeters; A M Tenbergen-Meekes; Dolf Evenberg; Jan Poolman; BJ Zegers; Ger T Rijkers
A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(12):4308-14.
1991: AF Verheul; AK Braat; J M Leenhouts; Peter Hoogerhout; Jan Poolman; Harm Snippe; Jan Verhoef
Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.
Infection and immunity 1991;59(3):843-51.
1990: D Muller; Jan Poolman; WE Bernadina; P J van Kol; E J Ruitenberg
Characterization of outer membrane proteins from Actinobacillus actinomycetemcomitans.
Microbial pathogenesis 1990;9(4):227-33.
1990: A Pettersson; Betsy Kuipers; M Pelzer; E Verhagen; R H Tiesjema; J Tommassen; Jan Poolman
Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.
Infection and immunity 1990;58(9):3036-41.
1990: Jan Poolman; Betsy Kuipers; M L Vogel; H J Hamstra; J Nagel
Description of a hybridoma bank towards Bordetella pertussis toxin and surface antigens.
Microbial pathogenesis 1990;8(6):377-82.
1990: Jan Tommassen; P Vermeij; M Struyvé; Roland Benz; Jan Poolman
Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins.
Infection and immunity 1990;58(5):1355-9.
1990: Jan Poolman
Polysaccharides and membrane vaccines.
Advances in biotechnological processes 1990;13():57-86.
1989: K Saukkonen; Maija Leinonen; H Abdillahi; Jan Poolman
Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay.
Vaccine 1989;7(4):325-8.
1989: B A Crowe; R A Wall; Barica Kusecek; B Neumann; T Olyhoek; H Abdillahi; M Hassan-King; B M Greenwood; Jan Poolman; Mark Achtman
Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa.
The Journal of infectious diseases 1989;159(4):686-700.
1989: Jan Poolman; hans timmermans; T Teerlink; R C Seid
Purification, cyanogen bromide cleavage, and amino terminus sequencing of class 1 and class 3 outer membrane proteins of meningococci.
Infection and immunity 1989;57(3):1005-7.
1989: M Pâques; J S Teppema; E C Beuvery; H Abdillahi; Jan Poolman; A J Verkleij
Accessibility of gonococcal and meningococcal surface antigens: immunogold labeling for quantitative electron microscopy.
Infection and immunity 1989;57(2):582-9.
1989: Helena Käyhty; Jan Poolman; H Abdillahi; A Sivonen; Juhani Eskola; E Tarkka; Heikki Peltola
Sero- and subtypes of group B meningococci causing invasive infections in Finland in 1976-87.
Scandinavian journal of infectious diseases 1989;21(5):527-35.
1988: H Abdillahi; Jan Poolman
Definition of meningococcal class 1 OMP subtyping antigens by monoclonal antibodies.
FEMS microbiology immunology 1988;1(3):139-44.
1988: B A Crowe; H Abdillahi; Jan Poolman; Mark Achtman
Correlation of serological typing and clonal typing methods for Neisseria meningitidis sero-group A.
Journal of medical microbiology 1988;26(3):183-7.
1988: H Abdillahi; Jan Poolman
Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA.
Journal of medical microbiology 1988;26(3):177-80.
1988: Jan Poolman
Meningococcal vaccines.
Journal of medical microbiology 1988;26(3):170-2.
1988: K Saukkonen; Maija Leinonen; Helena Käyhty; H Abdillahi; Jan Poolman
Monoclonal antibodies to the rough lipopolysaccharide of Neisseria meningitidis protect infant rats from meningococcal infection.
The Journal of infectious diseases 1988;158(1):209-12.
1988: Jan Poolman; H Abdillahi
Outer membrane protein serosubtyping of Neisseria meningitidis.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(2):291-2.
1988: H Abdillahi; B A Crowe; Mark Achtman; Jan Poolman
Two monoclonal antibodies specific for serotype 4 antigen of Neisseria meningitidis.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(2):293-6.
1988: Ger T Rijkers; J J Roord; M C Struyvé; Jan Poolman; BJ Zegers
Development of IgG antipolyribosylribitolphosphate antibodies in the course of H. influenzae type b meningitis in infants below 2 years of age.
Monographs in allergy 1988;23():282-8.
1988: H Abdillahi; Jan Poolman
Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA.
Microbial pathogenesis 1988;4(1):27-32.
1987: K Saukkonen; H Abdillahi; Jan Poolman; Maija Leinonen
Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development.
Microbial pathogenesis 1987;3(4):261-7.
1987: Jan Poolman; hans timmermans; C T Hopman; T Teerlink; P A Van Vught; M H Witvliet; E C Beuvery
Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide.
Antonie van Leeuwenhoek 1987;53(6):413-9.
1986: Jan Poolman; E C Beuvery; C T Hopman; M H Witvliet; hans timmermans; T Teerlink; H C Zanen
Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococci.
Developments in biological standardization 1986;63():147-52.
1985: Jan Poolman; C T Hopman; H C Zanen
Colony variants of Neisseria meningitidis strain 2996 (B:2b:P1.2): influence of class-5 outer membrane proteins and lipopolysaccharides.
Journal of medical microbiology 1985;19(2):203-9.
1983: Loek van Alphen; T Riemens; Jan Poolman; H C Zanen
Characteristics of major outer membrane proteins of Haemophilus influenzae.
Journal of bacteriology 1983;155(2):878-85.
1983: Loek van Alphen; T Riemens; Jan Poolman; C Hopman; H C Zanen
Homogeneity of cell envelope protein subtypes, lipopolysaccharide serotypes, and biotypes among Haemophilus influenzae type b from patients with meningitis in The Netherlands.
The Journal of infectious diseases 1983;148(1):75-81.
1983: Jan Poolman; C T Hopman; H C Zanen
Immunogenicity of meningococcal antigens as detected in patient sera.
Infection and immunity 1983;40(1):398-406.
1980: Jan Poolman; C T Hopman; H C Zanen
Immunochemical characterization of Neisseria meningitidis serotype antigens by immunodiffusion and SDS-polyacrylamide gel electrophoresis immunoperoxidase techniques and the distribution of serotypes among cases and carriers.
Journal of general microbiology 1980;116(2):465-73.